Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?

PURPOSE: Mutations affecting the KRAS gene are an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, the role of KRAS mutation as a biomarker for anti-vascular endothelial growth factor (VEGF) remains controv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Park, Kyong Hwa, Shin, Sang Won, Kim, Yeul Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918527/
https://www.ncbi.nlm.nih.gov/pubmed/24520223
http://dx.doi.org/10.4143/crt.2014.46.1.48

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918527/
https://www.ncbi.nlm.nih.gov/pubmed/24520223
http://dx.doi.org/10.4143/crt.2014.46.1.48

Ejemplares similares